In a rare misfire, Regeneron scraps its RSV drug after a PhIII failure
In a rare Phase III failure, Regeneron says its late-stage antibody for RSV — suptavumab (REGN2222) — flopped in a major study which enrolled more than a thousand healthy pre-term infants.
There won’t be a second act for this drug. Regeneron $REGN is scrapping the drug, once held up as one of its top Phase III prospects, and moving on.
Although researchers were able to tease out evidence of efficacy in one subgroup, they say the drug failed to significantly reduce the number of medically-attended RSV infections.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
